Meta-analysis of molecular targeted agents in the treatment of elderly patients with metastatic colorectal cancer: Does the age matter ?

Conclusions: The introduction of MTAs to therapies offered a survival benefit in elderly patients with mCRC. Further studies aimed at this specific patient population were still needed to watchfully monitor potential treatment-related toxicities to optimize the use of these drugs.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide. Although targeted therapy in combination with chemotherapy in CRC prolongs the overall survival of patients with metastatic disease, acquired resistance and relapse hinder their clinical benefits. Moreover, patients with some specific genetic profile are unlikely to benefit from targeted therapy, suggesting the need for safe and effective treatment strategies. Retinoids, comprising of natural and synthetic analogs, are a class of chemical compounds that regulate cellular proliferation, differentiation, and cell death. Retin...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Review Articles Source Type: research
Publication date: Available online 17 July 2019Source: Neuroscience LettersAuthor(s): Anamaria Falcão Pereira, Lus Mário Silva Pereira, Cristiane Maria Pereira Silva, Bruno Wesley Freitas Alves, Jéssica Sales Barbosa, Francisco Maxwell Martins Pinto, Ana Carolina Pereira, Karla Oliveira Silva, Renata Bessa Pontes, Nylane Maria Nunes Alencar, Roberto César Pereira Lima-Júnior, Mariana Lima ValeAbstractOxaliplatin is a third-generation platinum drug commonly used as the first line treatment of metastatic colorectal cancer. Oxaliplatin-based anticancer regimens course with dose-limiting neur...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancerCombination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trialmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trial
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news
ConclusionsComplete perioperative colonoscopy in patients with CRC should be performed to reduce the rate of metachronous carcinoma. Postoperative completion of preoperative insufficiently colonoscoped patients is recommended.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
AbstractPurposeWe conducted this large population-based study to investigate the prognostic significance of N1c.MethodsPatients diagnosed with colorectal cancer from the surveillance, epidemiology, and end results (SEER) database between January 1, 2010, and December 31, 2010, were included in the sample. The primary outcome of interest used in our study was cause-specific survival (CSS). Cox proportional hazards models and Kaplan –Meier methods were used to evaluate the prognostic value of N1c. Propensity score matching (PSM) was implemented to reduce the possibility of selection bias using a logistic regression mod...
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
AbstractPurposeMost elderly patients with colorectal cancer have comorbidities and reduced functional reserve, which may increase their risks of postoperative morbidity and mortality, and subsequently influence the treatment choice. Therefore, this study aimed to investigate the treatment choice and compare laparoscopic and open surgery in this setting.MethodsThis retrospective study evaluated 118 patients with colorectal cancer ( ≥ 85 years old between January 2007 and February 2018) to determine the influence of comorbidities on treatment choice, as well as the safety and feasibility of laparoscopic s...
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
We describe the management of cancer-associated IO near the end of life in a population-based cohort with universal health coverage. METHODS: Patients who died of gastric, colorectal, ovarian, and pancreatic cancers from 2002 to 2015 were identified from the Ontario Cancer Registry. Those with ≥1 hospital admission for IO in the final year of life were identified from administrative data. Management of IO at index admission was categorized as surgery, gastrostomy, stent, feeding jejunostomy, and medical management. Trends in management over the study period were assessed by the Cochran-Armitage test. RESULTS: Th...
Source: Journal of Palliative Care - Category: Palliative Care Tags: J Palliat Care Source Type: research
CONCLUSIONS: Contrary to earlier reports of lower-quality care, patients with and without mental illness had similar preventive and chronic disease management care quality following medical home implementation. PMID: 31310189 [PubMed - as supplied by publisher]
Source: Psychiatric Services - Category: Psychiatry Tags: Psychiatr Serv Source Type: research
(Northwestern University) Many of the deadliest or most common cancers get the least amount of nonprofit research funding, reports a new Northwestern Medicine study. 'Embarrassing' or stigmatized cancers, like lung and liver, are underfunded. Colon, endometrial, liver and bile duct, cervical, ovarian, pancreatic and lung cancers were all poorly funded compared to how common they are and how many deaths they cause, the study found. In contrast, breast cancer, leukemia, lymphoma and pediatric cancers were all well-funded, respective to their impact on society.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Medical Training Application Service | Study | Toxicology